Insider Shareholders with Direct Ownership of Bluebird Bio, Inc. (BLUE)
This section provides a comprehensive overview of the insiders with direct ownership of Bluebird Bio, Inc. (BLUE). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
bluebird bio, Inc. Insider List
| Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
|---|---|---|---|---|---|
|
Andrew Obenshain
President and CEO |
578,036 | 102,232 | 374,247 $2.92 Million | 26 |
Dec 10, 2024
Reduced 0.26%
|
| 406,449 | 25,419 | 315,839 $2.46 Million | 19 |
Nov 06, 2024
Added 7.31%
|
|
|
Jason Cole
Chief Strategy & Financial Off |
273,873 | 29,943 | 189,546 $1.48 Million | 18 |
Aug 19, 2022
Reduced 6.97%
|
| 216,192 | 23,192 | 170,000 $1.32 Million | 14 |
Sep 30, 2024
Reduced 0.59%
|
|
|
Richard A Colvin
Chief Medical Officer |
135,000 | 14,462 | 165,544 $1.29 Million | 10 |
Dec 10, 2024
Reduced 1.68%
|
|
Gina Consylman
Chief Financial Officer |
125,385 | 0 | 125,385 $976,749 | 2 |
Feb 01, 2022
Added 16.62%
|
|
O. James Sterling
Chief Financial Officer |
100,000 | 0 | 100,000 $779,000 | 1 |
Sep 30, 2024
Added 50.0%
|
|
Joseph Vittiglio
Chief Business & Legal Officer |
100,000 | 5,217 | 94,783 $738,359 | 3 |
Sep 30, 2024
Added 34.53%
|
|
Jessica Whitten
Chief Accounting Officer |
59,407 | 3,393 | 56,913 $443,352 | 6 |
Feb 01, 2022
Added 11.64%
|
| 48,149 | 0 | 51,364 $400,125 | 5 |
Nov 06, 2024
Added 32.65%
|
|
| 49,393 | 0 | 49,941 $389,040 | 5 |
Nov 06, 2024
Added 33.27%
|
|
| 52,823 | 0 | 48,160 $375,166 | 5 |
Nov 06, 2024
Added 34.08%
|
|
|
David Davidson
Chief Medical Officer |
12,271 | 4,251 | 47,787 $372,260 | 10 |
Apr 05, 2021
Reduced 0.09%
|
| 52,823 | 1,004 | 47,156 $367,345 | 6 |
Nov 06, 2024
Added 34.56%
|
|
|
Christopher Krawtschuk
Chief Financial Officer |
50,000 | 4,526 | 45,474 $354,242 | 2 |
Dec 06, 2023
Reduced 9.05%
|
| 43,462 | 0 | 43,462 $338,568 | 4 |
Nov 06, 2024
Added 36.42%
|
|
|
Anne Virginie Eggimann
Chief Regulatory Officer |
17,000 | 1,358 | 42,252 $329,143 | 2 |
Jul 12, 2022
Reduced 3.11%
|
| 37,350 | 0 | 37,350 $290,956 | 1 |
Sep 30, 2024
Added 50.0%
|
|
|
Philip D Gregory
Chief Scientific Officer |
95,314 | 3,817 | 34,127 $265,849 | 13 |
Nov 11, 2021
Added %
|
| 29,563 | 0 | 29,563 $230,295 | 2 |
Nov 06, 2024
Added 45.72%
|
|
|
Alison Cecily Finger
Chief Commercial Officer |
0 | 1,961 | 25,103 $195,552 | 5 |
Jan 06, 2021
Reduced 2.93%
|
|
William D Baird Iii
Chief Financial Officer |
96,578 | 2,858 | 22,797 $177,588 | 6 |
Nov 11, 2021
Added %
|
|
Joanne Smith Farrell
COO, Oncology |
0 | 1,442 | 20,609 $160,544 | 5 |
Jan 06, 2021
Reduced 2.54%
|
|
Wendy L Dixon
Director |
9,350 | 0 | 11,894 $92,654 | 2 |
Nov 11, 2021
Added 34.41%
|
|
Daniel Lynch
Director |
4,353 | 0 | 7,959 $62,000 | 2 |
Nov 11, 2021
Added %
|
|
Katy Burnett
Principal Accounting Officer |
3,427 | 641 | 4,097 $31,915 | 3 |
Feb 17, 2021
Reduced 11.22%
|
|
William R. Sellers
Director |
3,766 | 0 | 3,601 $28,051 | 2 |
Nov 11, 2021
Added %
|
|
Denice Torres
Director |
4,585 | 0 | 2,726 $21,235 | 2 |
Nov 11, 2021
Added %
|
|
Sarah Js Glickman
Director |
4,663 | 0 | 0 $0 | 2 |
Nov 11, 2021
Added %
|
|
Ramy Ibrahim
Director |
5,359 | 0 | 0 $0 | 3 |
Nov 11, 2021
Added %
|
|
Marcela V. Maus
Director |
4,663 | 0 | 0 $0 | 2 |
Nov 11, 2021
Added %
|